Table 1.
Baseline data of patients in the different treatment groups
|
Project
|
GTG
|
ITG
|
t value
|
P value
|
| Male:Female | 60:40 | 61:39 | 0.021 | 0.885 |
| Age (yr) | 33.15 ± 9.91 | 34.42 ± 10.04 | -0.901 | 0.369 |
| DBP (mmHg) | 93.05 ± 6.98 | 93.03 ± 7.73 | 0.019 | 0.985 |
| SBP (mmHg) | 140.60 ± 9.94 | 141.40 ± 11.17 | -0.535 | 0.593 |
| K (mmol/L) | 4.88 ± 0.97 | 4.72 ± 0.96 | 1.149 | 0.252 |
| Hb (g/L) | 128.60 ± 14.97 | 129.65 ± 16.29 | -0.472 | 0.638 |
| GFR (mL-1min-1∙(1.73∙m2)-1) | 55.36 ± 3.34 | 54.70 ± 3.27 | 1.405 | 0.162 |
| ALT (U/L) | 36.53 ± 3.20 | 37.12 ± 3.30 | -1.279 | 0.203 |
| T-CHO (mmol/L) | 5.59 ± 0.99 | 5.55 ± 0.99 | 0.321 | 0.748 |
| Glu (mmol/L) | 5.19 ± 0.69 | 5.10 ± 0.66 | 0.883 | 0.378 |
| BMI (kg/m2) | 23.06 ± 2.51 | 23.29 ± 2.55 | -0.717 | 0.474 |
| Alb (g/L) | 22.94 ± 3.20 | 23.11 ± 3.02 | -0.402 | 0.688 |
| 24-h urinary protein quantification (g) | 4.01 ± 1.43 | 3.86 ± 1.37 | 0.76 | 0.448 |
| Scr (μmol/L) | 121.51 ± 14.58 | 122.16 ± 15.29 | -0.311 | 0.756 |
GTG: Glucocorticoid therapy group; ITG: Immunosuppressive therapy group; DBP: Diastolic blood pressure; SBP: Systolic blood pressure; Scr: Serum creatinine; UA: Blood uric acid; BLA: Blood albumin; K: Blood potassium; Hb: Hemoglobin; eGFR: Glomerular filtration rate; ALT: Alanine aminotransferase; T-CHO: Total cholesterol; Glu: Fasting blood glucose; BMI: Body mass index.